NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
23.98
+1.05 (4.58%)
Jul 23, 2025, 4:00 PM - Market closed

Company Description

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.

It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company logo
CountryNetherlands
Founded2019
IndustryBiotechnology
SectorHealthcare
Employees68
CEOMichael Davidson

Contact Details

Address:
Gooimeer 2-35
Naarden, 1411 DC
Netherlands
Phone31 35 206 2971
Websitenewamsterdampharma.com

Stock Details

Ticker SymbolNAMS
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001936258
ISIN NumberNL00150012L7
SIC Code2834

Key Executives

NamePosition
Dr. Michael Harvey Davidson FACC, Facp., M.D.Chief Executive Officer, President, Executive Board Member and Director
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.Founder, Chief Scientific Officer, Member of Executive Board and Director
Mayur Amrat SomaiyaChief Financial Officer
Douglas F. KlingChief Operating Officer
Juliette Audet M.B.A., M.Sc.Chief Strategy and Business Officer
Louise KooijChief Accounting Officer
Matthew PhilippeExecutive Vice President &Head of Investor Relations
Bob RamboExecutive Vice President of Marketing
Maryellen McQuadeChief People Officer
Dr. Marc Ditmarsch M.D.Chief Development Officer

Latest SEC Filings

DateTypeTitle
Jul 14, 2025144Filing
Jul 11, 20258-KCurrent Report
Jun 18, 2025144Filing
Jun 11, 20258-KCurrent Report
Jun 9, 20258-KCurrent Report
Jun 6, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025144Filing
May 13, 2025SCHEDULE 13GFiling
May 8, 2025ARSFiling